



## SECURE-AD update

We are incredibly grateful for your ongoing contributions to the international atopic dermatitis and COVID-19 reporting registries: the SECURE-AD Registry and SECURE-AD Patient Survey. Hereby we share our latest update.




There are currently **198** cases reported in the SECURE-AD Registry and **135** completed Patient Surveys.

**SECURE-AD Registry** - please continue to report any cases of suspected or confirmed COVID-19 in patients with atopic dermatitis.

**SECURE-AD Patient Survey** - please encourage your patients with atopic dermatitis with suspected or confirmed COVID-19 to complete the SECURE-AD Patient Survey.


### Current data - SECURE-AD Registry

AD treatment




- Topical treatment only
- Conventional systemics
- Dupilumab

AD severity before COVID-19



- Clear
- Moderate
- Mild
- Severe


Adverse COVID-19 outcomes



Analysed data of 145 patients


### Current data - SECURE-AD Patient Survey

AD severity before COVID-19




- Clear
- Moderate
- Mild
- Severe

Change in AD severity during COVID-19



- Not sure
- Worsened
- Improved
- No change

Adverse COVID-19 outcomes



Analysed data of 120 patients

